GB0130704D0 - New use - Google Patents

New use

Info

Publication number
GB0130704D0
GB0130704D0 GBGB0130704.0A GB0130704A GB0130704D0 GB 0130704 D0 GB0130704 D0 GB 0130704D0 GB 0130704 A GB0130704 A GB 0130704A GB 0130704 D0 GB0130704 D0 GB 0130704D0
Authority
GB
United Kingdom
Prior art keywords
new use
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0130704.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB0130704.0A priority Critical patent/GB0130704D0/en
Publication of GB0130704D0 publication Critical patent/GB0130704D0/en
Priority to EP02788193A priority patent/EP1465650A2/en
Priority to JP2003556081A priority patent/JP2005524615A/en
Priority to PCT/GB2002/005813 priority patent/WO2003055505A2/en
Priority to AU2002352477A priority patent/AU2002352477A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
GBGB0130704.0A 2001-12-21 2001-12-21 New use Ceased GB0130704D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0130704.0A GB0130704D0 (en) 2001-12-21 2001-12-21 New use
EP02788193A EP1465650A2 (en) 2001-12-21 2002-12-19 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders
JP2003556081A JP2005524615A (en) 2001-12-21 2002-12-19 New use
PCT/GB2002/005813 WO2003055505A2 (en) 2001-12-21 2002-12-19 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders
AU2002352477A AU2002352477A1 (en) 2001-12-21 2002-12-19 Sk-3 potassium channels and the treatment of sexual dysfunctions and/or vascular disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0130704.0A GB0130704D0 (en) 2001-12-21 2001-12-21 New use

Publications (1)

Publication Number Publication Date
GB0130704D0 true GB0130704D0 (en) 2002-02-06

Family

ID=9928209

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0130704.0A Ceased GB0130704D0 (en) 2001-12-21 2001-12-21 New use

Country Status (5)

Country Link
EP (1) EP1465650A2 (en)
JP (1) JP2005524615A (en)
AU (1) AU2002352477A1 (en)
GB (1) GB0130704D0 (en)
WO (1) WO2003055505A2 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505611A (en) * 1995-03-14 1998-06-02 ヴィヴァス・インコーポレーテッド Methods and kits for preventing erectile dysfunction
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6197801B1 (en) * 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
FR2774593B1 (en) * 1998-02-12 2000-05-05 Philippe Gorny OBTAINING A MEDICINE TO COMBAT FEMALE SEXUAL DYSFUNCTIONS
US6194447B1 (en) * 1998-07-02 2001-02-27 Neurosearch A/S Bis (benzimidazole) derivatives serving as potassium blocking agents
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
MXPA01010021A (en) * 1999-04-06 2002-07-30 Zonagen Inc Methods for modulating the human sexual response.
AU5390900A (en) * 1999-06-29 2001-01-22 Neurosearch A/S Potassium channel blocking agents

Also Published As

Publication number Publication date
AU2002352477A8 (en) 2003-07-15
WO2003055505A2 (en) 2003-07-10
AU2002352477A1 (en) 2003-07-15
WO2003055505A3 (en) 2003-11-27
JP2005524615A (en) 2005-08-18
EP1465650A2 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
DE60217478D1 (en) Sychrongleichrichter
EP1387687A4 (en) Novel use
GB0125088D0 (en) New use
GB0115181D0 (en) Novel use
GB0100762D0 (en) Novel use
GB0104554D0 (en) New uses
IL153176A0 (en) New phenylpiperazines
GB0106031D0 (en) Use
PL364090A1 (en) New benzylaminopyrimidines
GB0119920D0 (en) New use
GB0117913D0 (en) New use
GB0115989D0 (en) New use
GB0130704D0 (en) New use
GB0119693D0 (en) New Use
GB0119822D0 (en) New use
GB0129834D0 (en) New use
GB0114008D0 (en) New therapautic use
GB0112208D0 (en) New use
GB0112207D0 (en) New use
GB0115598D0 (en) New use
GB0117918D0 (en) New use
GB0119928D0 (en) New use
GB0103899D0 (en) Use
GB0126186D0 (en) Use
GB0102482D0 (en) Use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)